Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | NQO1 | P15559 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24700745 | 0.92 | MMP12 (0.33) | MMP12MMP13KDM4EMEN1ALDH1A1 | |
| SCHEMBL23473699 | 0.83 | AHR (0.40) | MMP12MMP13NUDT1HCRTR1KDM4E | |
| SCHEMBL24475111 | 0.82 | MEN1 (0.39) | NUDT1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL21086068 | 0.78 | ADORA2A (0.30) | KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL18232158 | 0.78 | ADORA2A (0.42) | DHODHNUDT1KDM4EMEN1ALDH1A1 | |
| SCHEMBL23183914 | 0.77 | MEN1 (0.41) | NUDT1MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL19862788 | 0.76 | HSP90AA1 (0.41) | NUDT1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL24701205 | 0.75 | ADORA2A (0.34) | DHODHKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL26936075 | 0.74 | ADORA2A (0.39) | NUDT1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL23719258 | 0.73 | ADORA2A (0.33) | DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220173330-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | DUPONT SPECIALTY MATERIALS KOREA LTD. (KR) | 2022-06-02 | — | — | US | disclosed |
| US-20210320263-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND, A PLURALITY OF HOST MATERIALS, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | DUPONT SPECIALTY MATERIALS KOREA LTD. (KR) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220173330-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | LEF1, ODC1, OR10J3 | MMP12 4321/4885MMP13 4812/4885DHODH 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.